Annual Review of Cancer Biology

Papers
(The median citation count of Annual Review of Cancer Biology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
55
44
Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor–Based Cellular Therapy25
Immune Cell Metabolism and Immuno-Oncology23
Tracing and Targeting the Origins of Childhood Cancer22
Distinct Essentiality of the Mitochondrial Respiratory Chain in Proliferating Cells in Vivo19
Not All Carcinogens Are Directly Mutagenic: A Holistic View of the Environmental Exposure–Cancer Connection18
Development of PROTAC Degrader Drugs for Cancer18
Clonal Hematopoiesis: Confluence of Malignant and Nonmalignant Diseases18
The Metabolic Relationship Between Viral Infection and Cancer15
RAS and SHOC2 Roles in RAF Activation and Therapeutic Considerations13
Therapeutic Targeting of the Menin–KMT2A Interaction13
Gut Microbiota in Colorectal Cancer: Associations, Mechanisms, and Clinical Approaches13
YAP, TAZ, and Hippo-Dysregulating Fusion Proteins in Cancer12
Applications of Digital Pathology in Cancer: A Comprehensive Review12
Next-Generation Therapies for Multiple Myeloma12
Advances in Therapies Targeting Inhibitory Checkpoint Receptors: TIGIT, LAG-3, and Beyond11
Studying Progression from Chronic Injury to Esophageal Adenocarcinoma10
Central Role of the Antigen-Presentation and Interferon-γ Pathways in Resistance to Immune Checkpoint Blockade10
New Tools for Lineage Tracing in Cancer In Vivo10
9
Complex Roles of PTPN11/SHP2 in Carcinogenesis and Prospect of Targeting SHP2 in Cancer Therapy9
Relationships Between Regeneration, Wound Healing, and Cancer8
Rationales for Combining Therapies to Treat Cancer: Independent Action, Response Correlation, and Collateral Sensitivity Versus Synergy8
Chemical Proteomics–Guided Discovery of Covalent Ligands for Cancer Proteins7
Biological, Diagnostic, and Therapeutic Insights from (Epi)Genomic Profiling of Pediatric Brain Tumors7
An Erratic Path Toward Discovery7
Germline Predisposition to Hematopoietic Malignancies: An Overview7
CAR NK Cells: The Future Is Now5
Insights into Leukemia from Single-Cell Genomics5
The Effects of Clonal Heterogeneity on Cancer Immunosurveillance5
Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy5
The Blood-Brain Barrier: Implications for Experimental Cancer Therapeutics4
Deciphering the Warburg Effect: Metabolic Reprogramming, Epigenetic Remodeling, and Cell Dedifferentiation4
Development of Tissue-Agnostic Treatments for Patients with Cancer3
The Intestinal Microbiota and Therapeutic Responses to Immunotherapy3
Allogeneic CAR T Cell Therapy for Cancer3
Strategies for Heating Up Cold Tumors to Boost Immunotherapies2
0.19053292274475